Allyon Capitol Partners

ImmuRx has developed an original immunotherapy platform for cancer and infectious disease, which, for the first time, links the two halves of the immune system. Adjuvants, which stimulate the immune system, and antigens, which direct the response to a specific target, now work together in ImmuRx’s new platform. The company has received a patent for this unique development.

Allyon Capital Partners’ investment in ImmuRx has been added to a $329,000 National Institutes of Health SBIR grant that the company was awarded in April 2009 to develop their lead compound, hCD40, and to expand their patent portfolio. While the hCD40 compound is intended to strengthen vaccines in treating metastatic melanoma, its applications could be even broader, with potential to target cancer stem cells, bacterial or viral infections, and HIV/AIDS viruses.

The immune system is composed of an ancient line of “innate” defenses conserved from the distant past (antigens), and an “acquired” set of selective defenses that can generate billions of permutations to fight a pathogen (adjuvants). ImmuRx’s vaccine candidate is intended to activate both parts of the system. To date, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.

The company’s management team has the needed experience in business development, IP protection, drug discovery, and human clinical trial execution to develop a proprietary compound with the potential to make a dramatic impact in medicine:

CEO: David DeLucia. Former CEO of MIST Inc., a breast cancer imaging company. Over 25 years in biopharmaceuticals, including business development at Millennium Pharmaceuticals, pre-clinical program management, and emerging technology development.

Chief Scientific Officer: Randolph Noelle, PhD, Chairman of the Immunology Department and Co-Director of the Cancer Immunotherapy Center at the Dartmouth Medical School. Discovered CD40 ligand, 1992. Over 50 CD40 related patents issued. Focused on cancer applications.

Vice President of Research: Hillary White, PhD, Associate Professor at Dartmouth Medical School and co-founder of White Mountain Pharma.

Director of R&D: Ross Kedl, PhD, Associate Professor, Colorado University. Co-PI, National BioDefense Respiratory Research Laboratory. Led the development of TLR agonists at 3M Pharmaceuticals. Focused on infectious disease applications.

Business Advisor: Michael Ross, PhD, is a Managing Partner at SV Life Sciences. He advises ImmuRx as a member of Dartmouth’s Thayer Board of Overseers. Michael was the 10th employee at Genentech, where he was team leader for Humulin®, Roferon® , Protropin®, and VP of Development during the development of Activase®, Nutropin® & Pulmozyme®.

Intellectual Property Counsel: Robin Teskin, Partner, Hunton Williams. Former US PTO examiner awarded Bronze Medal for distinguished service. Over 100 CD40 related patents prosecuted worldwide.

Click here for more Investment info

www.immurx.com